T-7802 Tandutinib, Free Base, >99%

Related Terms : [MLN518] [CT53518]

  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 36
  • 32
  • 24
  • 4,000
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 55
  • 49
  • 37
  • 6,100
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 92
  • 82
  • 63
  • 10,200
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 166
  • 149
  • 113
  • 18,500
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 298
  • 267
  • 204
  • 33,100
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 486
  • 436
  • 332
  • 54,000
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 562.70
  • C31H42N6O4
  • [387867-13-2]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 25 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM; buffers, serum, or other additives may increase or dec. Disposal: A.

  • Tandutinib (also known as MLN518 or CT53518) is an orally active inhibitor of Fms-like tyrosine kinase 3 (FLT3) kinase, PDGFRβ and c-Kit. It inhibits FLT3 phosphorylation, downstream signaling and tumor growth in vitro and in animal models. Cheng, Y. and Paz, K. "Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications." IDrugs 11: 46-56 (2008).
  • The sensitivity of cell lines to tandutinib is increased by FLT3 siRNA-induced down-regulation of FLT3. Walters, D.K., et al. "RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518." Blood 105: 2952-2954 (2005).
  • In human FLT3-ITD-positive acute myelogenous leukemia (AML) cell lines, tandutinib induced apoptosis and inhibited FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways. In Ba/F3 cells expressing different FLT3-ITD mutants, tandutinib also demonstrated inhibition of IL-3-independent cell growth and FLT3-ITD autophosphorylation, with an IC50 of 10-100 nM. Tandutinib was a potent inhibitor of FLT3-ITD-induced disease in a murine model. Kelly, L.M., et al. "CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)." Cancer Cell 1: 421-432 (2002).
  • Tandutinib inhibits the growth of blast colonies from FLT3 ITD-positive patients with acute myelocytic leukemia (AML) more effectively than for blast colonies from ITD-negative AML patients, at concentrations that do not significantly block colony formation of normal human progenitor cells. Tandutinib has moderate toxicity toward normal hematopoiesis at concentrations that are used in treating FLT3 ITD-positive leukemia in mice. Griswold, I.J., et al. "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis." Blood 104: 2912-2918 (2004).
  • Tandutinib inhibited FLT3 autophosphorylation and phosphorylation of STAT5 and ERK in FLT3-ITD-transformed Ba/F3 cells (IC50 = 500 nM). However, there was a broad spectrum of sensitivity among the 8 activation loop mutants (IC50 = 500 nM - 10 µM) for the inhibition of phosphorylation of FLT3, STAT5, and ERK. The relative cellular sensitivity of the mutants to tandutinib for proliferation of FLT3-transformed Ba/F3 cells correlated with IC50s in the biochemical assays, indicating that certain activation loop mutations in FLT3 confer resistance to tandutinib. Clark, J.J., et al. "Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518." Blood 104: 2867-2872 (2004).
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
297